Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 1364 results for social care

  1. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  2. Public board meeting agenda and papers: May 2023

    Agenda and papers of the NICE public board meeting on 17 May 2023

  3. Public board meeting agenda and papers: July 2024

    Agenda and papers of the NICE public board meeting on 17 July 2024

  4. Public board meeting agenda and papers: December 2022

    Agenda and papers of the NICE public board meeting on 16 December 2022

  5. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  6. Is contingency management effective in reducing alcohol consumption in people who misuse alcohol compared with standard care?

    reducing alcohol consumption in people who misuse alcohol compared with standard care? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    9 June 2015

  7. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  8. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued

  9. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  10. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development Reference number: GID-TA10822 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Is acupuncture effective in reducing alcohol consumption compared with standard care?

    acupuncture effective in reducing alcohol consumption compared with standard care? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    9 June 2015

  14. FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)

    NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .

    Medtech innovation briefing
    Published
    26 August 2020

  15. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued